View ValuationT.Man Pharmaceutical 将来の成長Future 基準チェック /16T.Man Pharmaceuticalは、3%と8.2%でそれぞれ年率3%で利益と収益が成長すると予測される一方、EPSはgrowで3.1%年率。主要情報3.0%収益成長率3.12%EPS成長率Pharmaceuticals 収益成長15.1%収益成長率8.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日14 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 18First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: EPS: ฿0.29 (down from ฿0.30 in 1Q 2025). Revenue: ฿633.7m (up 5.8% from 1Q 2025). Net income: ฿114.6m (down 6.0% from 1Q 2025). Profit margin: 18% (down from 20% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • May 01Upcoming dividend of ฿0.32 per shareEligible shareholders must have bought the stock before 08 May 2026. Payment date: 26 May 2026. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 2.5%. Lower than top quartile of Thai dividend payers (7.5%). Higher than average of industry peers (1.9%).Reported Earnings • Mar 02Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ฿1.31. Revenue: ฿2.53b (up 14% from FY 2024). Net income: ฿523.1m (up 16% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.Declared Dividend • Mar 02Final dividend of ฿0.32 announcedShareholders will receive a dividend of ฿0.32. Ex-date: 8th May 2026 Payment date: 26th May 2026 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Payout Ratios Payout ratio: 17%. Cash payout ratio: 73%.お知らせ • Feb 27T.Man Pharmaceutical Public Company Limited Proposes Interim Cash Dividend for the Period from January 1, 2025 to December 31, 2025, Payable on May 26, 2026T.Man Pharmaceutical Public Company Limited proposed to the 2026 Annual General Meeting of Shareholders to acknowledge the interim dividend payment that has already been paid during the year, and it is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the allocation of profits for the payment of the remaining cash dividend at the rate of THB 0.32 per share, totaling THB 128,001,152 for the Company's ordinary shares of 400,003,600 shares Paid from Operating period from January 1, 2025 to December 31, 2025. Such dividend will be paid from the Company's unallocated net profit, which is the net profit of the business that has paid corporate income tax at the rate of 20%. In this regard, individual shareholders are entitled to tax credits in calculating dividend tax according to Section 47 bis of the Revenue Code. The annual dividend payment for 2025, including both the interim dividend and this dividend, represents 60.78% of the net profit for the year 2025. In this regard, the Board has resolved to set the Record Date for shareholders entitled to receive dividends on 11 May 2026, and the dividend payment date on 26 May 2026. However, the right to receive such dividend is subject to approval from the 2026 Annual General Meeting of Shareholders. Ex-dividend date: May 8, 2026.お知らせ • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026, at 14:00 SE Asia Standard Time.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.28 (vs ฿0.32 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.28. Revenue: ฿661.4m (up 23% from 3Q 2024). Net income: ฿112.6m (up 8.1% from 3Q 2024). Profit margin: 17% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • Aug 19Upcoming dividend of ฿0.24 per shareEligible shareholders must have bought the stock before 26 August 2025. Payment date: 09 September 2025. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Thai dividend payers (7.9%). In line with average of industry peers (1.7%).Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.27 (vs ฿0.30 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.27. Revenue: ฿535.5m (up 2.8% from 2Q 2024). Net income: ฿106.8m (up 8.0% from 2Q 2024). Profit margin: 20% (in line with 2Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ฿0.30 (down from ฿0.42 in 1Q 2024). Revenue: ฿599.0m (up 1.7% from 1Q 2024). Net income: ฿121.9m (down 13% from 1Q 2024). Profit margin: 20% (down from 24% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Asia.お知らせ • May 08T.Man Pharmaceutical Public Company Limited announces Annual dividend, payable on May 23, 2025T.Man Pharmaceutical Public Company Limited announced Annual dividend of THB 0.1800 per share payable on May 23, 2025, ex-date on May 06, 2025 and record date on May 07, 2025.Reported Earnings • Feb 27Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: ฿1.31. Revenue: ฿2.23b (up 12% from FY 2023). Net income: ฿450.7m (up 4.5% from FY 2023). Profit margin: 20% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%.お知らせ • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025, at 14:00 SE Asia Standard Time.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿12.60, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Pharmaceuticals industry in Asia.Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: ฿0.31 (vs ฿0.33 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.31. Revenue: ฿535.8m (up 13% from 3Q 2023). Net income: ฿104.2m (up 16% from 3Q 2023). Profit margin: 19% (in line with 3Q 2023).お知らせ • Oct 23T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion.T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,994,100 Price\Range: THB 16.3 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,005,900 Price\Range: THB 16.3Board Change • Oct 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.業績と収益の成長予測SET:TMAN - アナリストの将来予測と過去の財務データ ( )THB Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20272,977555N/AN/A112/31/20262,757504N/AN/A112/31/20252,526523110336N/A9/30/20252,376449306483N/A6/30/20252,250441350505N/A3/31/20252,236433341516N/A12/31/20242,226451346520N/A9/30/20242,197433313514N/A6/30/20242,130419239416N/A3/31/20242,089445195384N/A12/31/20231,98043162282N/A9/30/20231,90341697387N/A6/30/20231,982494269597N/A3/31/20232,003483279560N/A12/31/20222,025473289524N/A12/31/20211,26356196276N/A12/31/202090160129194N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TMANの予測収益成長率 (年間3% ) は 貯蓄率 ( 2.2% ) を上回っています。収益対市場: TMANの収益 ( 3% ) TH市場 ( 10.9% ) よりも低い成長が予測されています。高成長収益: TMANの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: TMANの収益 ( 8.2% ) TH市場 ( 10.1% ) よりも低い成長が予測されています。高い収益成長: TMANの収益 ( 8.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TMANの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/19 17:51終値2026/06/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋T.Man Pharmaceutical Public Company Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Theethanat JindaratYuanta Securities (Thailand) Company LimitedKritawit RatanakhanokchaiYuanta Securities (Thailand) Company LimitedAthitaya ChinakanjanaditYuanta Securities (Thailand) Company Limited1 その他のアナリストを表示
Reported Earnings • May 18First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: EPS: ฿0.29 (down from ฿0.30 in 1Q 2025). Revenue: ฿633.7m (up 5.8% from 1Q 2025). Net income: ฿114.6m (down 6.0% from 1Q 2025). Profit margin: 18% (down from 20% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • May 01Upcoming dividend of ฿0.32 per shareEligible shareholders must have bought the stock before 08 May 2026. Payment date: 26 May 2026. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 2.5%. Lower than top quartile of Thai dividend payers (7.5%). Higher than average of industry peers (1.9%).
Reported Earnings • Mar 02Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ฿1.31. Revenue: ฿2.53b (up 14% from FY 2024). Net income: ฿523.1m (up 16% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
Declared Dividend • Mar 02Final dividend of ฿0.32 announcedShareholders will receive a dividend of ฿0.32. Ex-date: 8th May 2026 Payment date: 26th May 2026 Dividend yield will be 4.3%, which is higher than the industry average of 2.4%. Payout Ratios Payout ratio: 17%. Cash payout ratio: 73%.
お知らせ • Feb 27T.Man Pharmaceutical Public Company Limited Proposes Interim Cash Dividend for the Period from January 1, 2025 to December 31, 2025, Payable on May 26, 2026T.Man Pharmaceutical Public Company Limited proposed to the 2026 Annual General Meeting of Shareholders to acknowledge the interim dividend payment that has already been paid during the year, and it is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the allocation of profits for the payment of the remaining cash dividend at the rate of THB 0.32 per share, totaling THB 128,001,152 for the Company's ordinary shares of 400,003,600 shares Paid from Operating period from January 1, 2025 to December 31, 2025. Such dividend will be paid from the Company's unallocated net profit, which is the net profit of the business that has paid corporate income tax at the rate of 20%. In this regard, individual shareholders are entitled to tax credits in calculating dividend tax according to Section 47 bis of the Revenue Code. The annual dividend payment for 2025, including both the interim dividend and this dividend, represents 60.78% of the net profit for the year 2025. In this regard, the Board has resolved to set the Record Date for shareholders entitled to receive dividends on 11 May 2026, and the dividend payment date on 26 May 2026. However, the right to receive such dividend is subject to approval from the 2026 Annual General Meeting of Shareholders. Ex-dividend date: May 8, 2026.
お知らせ • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 29, 2026, at 14:00 SE Asia Standard Time.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ฿0.28 (vs ฿0.32 in 3Q 2024)Third quarter 2025 results: EPS: ฿0.28. Revenue: ฿661.4m (up 23% from 3Q 2024). Net income: ฿112.6m (up 8.1% from 3Q 2024). Profit margin: 17% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • Aug 19Upcoming dividend of ฿0.24 per shareEligible shareholders must have bought the stock before 26 August 2025. Payment date: 09 September 2025. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Thai dividend payers (7.9%). In line with average of industry peers (1.7%).
Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: ฿0.27 (vs ฿0.30 in 2Q 2024)Second quarter 2025 results: EPS: ฿0.27. Revenue: ฿535.5m (up 2.8% from 2Q 2024). Net income: ฿106.8m (up 8.0% from 2Q 2024). Profit margin: 20% (in line with 2Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ฿0.30 (down from ฿0.42 in 1Q 2024). Revenue: ฿599.0m (up 1.7% from 1Q 2024). Net income: ฿121.9m (down 13% from 1Q 2024). Profit margin: 20% (down from 24% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Asia.
お知らせ • May 08T.Man Pharmaceutical Public Company Limited announces Annual dividend, payable on May 23, 2025T.Man Pharmaceutical Public Company Limited announced Annual dividend of THB 0.1800 per share payable on May 23, 2025, ex-date on May 06, 2025 and record date on May 07, 2025.
Reported Earnings • Feb 27Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: ฿1.31. Revenue: ฿2.23b (up 12% from FY 2023). Net income: ฿450.7m (up 4.5% from FY 2023). Profit margin: 20% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%.
お知らせ • Feb 26T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025T.Man Pharmaceutical Public Company Limited, Annual General Meeting, Apr 25, 2025, at 14:00 SE Asia Standard Time.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ฿12.60, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 17x in the Pharmaceuticals industry in Asia.
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: ฿0.31 (vs ฿0.33 in 3Q 2023)Third quarter 2024 results: EPS: ฿0.31. Revenue: ฿535.8m (up 13% from 3Q 2023). Net income: ฿104.2m (up 16% from 3Q 2023). Profit margin: 19% (in line with 3Q 2023).
お知らせ • Oct 23T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion.T.Man Pharmaceutical Public Company Limited has completed an IPO in the amount of THB 1.6626 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,994,100 Price\Range: THB 16.3 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,005,900 Price\Range: THB 16.3
Board Change • Oct 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.